secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUTRO BIOPHARMA, INC. (STRO)
CIK:        0001382101
Form:       8-K
Filed at:   2025-06-02T23:59:59+00:00
Accession:  0001193125-25-133268
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Sutro Biopharma appoints Gregory K. Chow as CFO effective June 2, 2025
----------------------------------------------------------------------

- Gregory K. Chow appointed CFO, principal financial and accounting officer, effective June 2, 2025.
- Base salary $475,000; target annual bonus 40% of base salary.
- Receives option for 275,000 shares (4-year vest) and 100,000 RSUs (4-year vest).
- Prior roles: CFO of NodThera (Aug 2024-Mar 2025), Freenome (Jan-Aug 2024), Frontier Medicines (Mar 2021-Dec 2024).
- Severance on non-cause termination: 15 months salary + pro-rata bonus + COBRA; full acceleration upon change in control within 18 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1382101/000119312525133268/0001193125-25-133268-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1382101/000119312525133268/d945851d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-133268

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer